Does immunostimulatory CpG-DNA and PSA-peptide vaccination elicit profound cytotoxic T cell responses?
CpG-DNA acts as potent adjuvant for vaccination therapies and elicits profound PSA-peptide specific CTL responses in combination with an immunodominant PSA-peptide. CpG-ODN mediated immunotherapy represents a potentially inexpensive, safe, easy-to-produce, and easy-to-handle treatment alternative. Therefore, further evaluation of CpG-DNA in immunization therapies against CaP is warranted.
Multiple cellular genes can modify risk for retinoblastoma in mice.